Debiopharm and Ascenta in a deal to develop early-stage anticancer compound
This article was originally published in Scrip
Executive Summary
The Swiss Debiopharm Group and US-based Ascenta Therapeutics have entered into an exclusive worldwide license development and commercialisation agreement for the Phase I compound, AT-406 (also, Debio 1143) for the treatment of various cancers.